BioSpace News Archive

Global pharmaceutical company Mylan N.V. announced four scientific abstracts from the Wixela™ Inhub™ development program that will be presented at the 2019 American Thoracic Society International Conference in Dallas, May 17 – May 22.

Janssen Pharmaceutical Companies of Johnson & Johnson presented new real-world data at the American Psychiatric Association 2019 Meeting which suggest that, among adult patients with major depressive disorder, psychiatric treatment in the year prior to a diagnosis of suicide ideation or attempt is markedly low.

The Medicines Company announced interim results from the ongoing ORION-3 open-label extension study which showed that twice-a-year dosing with inclisiran sodium 300 mg resulted in consistent lowering of low density lipoprotein cholesterol by more than 50 percent with overall follow-up of up to three years.

ACADIA Pharmaceuticals Inc. announced it will present data from its Phase 2 CLARITY study, which evaluated the efficacy, safety, and tolerability of pimavanserin as an adjunctive treatment for major depressive disorder at the 2019 American Psychiatric Association Annual Meeting in San Francisco, May 18 – 22, 2019.

Cook Medical and Ambu A/S have agreed on terms to enter into a partnership under which Cook will distribute Ambu’s single-use, disposable duodenoscope in the U.S., following FDA clearance.